GlassScriptPhysician profile
Shane Michael Gleaves
NPI 1538897392
$2,772.22
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.04 · 2023: $961 · 2024: $1,395 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,691.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $318.31 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $297.71 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $256.33 | 2022-2025 | |
| Novo Nordisk INC | $253.34 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $220.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $196.12 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Axsome Therapeutics, INC. | $161.10 | 2023-2025 | Auvelity |
| Amgen INC. | $148.38 | 2024-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.30 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $101.59 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $99.45 | 2023-2025 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $86.20 | 2022-2025 | |
| Abbvie INC. | $60.37 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.65 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $54.86 | 2024 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $51.68 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $46.75 | 2023 | Belsomra, Januvia, Verquvo |
| Sumitomo Pharma America, INC. | $43.58 | 2023-2024 | Gemtesa |
| Tris Pharma INC | $40.94 | 2024 | Dyanavel Xr |
| Nevro Corp. | $39.93 | 2022-2023 | Senza |
| Eisai INC. | $23.95 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $22.42 | 2023 | Opsumit |
| Medtronic, INC. | $17.81 | 2025 | Inceptiv |
| Phadia US INC. | $16.26 | 2023 | Immunocap |
| E.R. Squibb & Sons, L.L.C. | $14.58 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2024 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $13.51 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Gleaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.